Ensysce Biosciences Said On June 13 Notified By Nasdaq That Company Has Regained Compliance With Equity Requirement In Nasdaq Listing Rule 5550(B)(10)
Portfolio Pulse from Charles Gross
Ensysce Biosciences has regained compliance with the equity requirement in Nasdaq Listing Rule 5550(B)(10), as notified by Nasdaq on June 13.
June 14, 2023 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences regains compliance with Nasdaq Listing Rule 5550(B)(10), which may positively impact its stock price.
Regaining compliance with Nasdaq Listing Rule 5550(B)(10) is a positive development for Ensysce Biosciences, as it ensures the company's continued listing on the Nasdaq exchange. This news may lead to increased investor confidence and a potential boost in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100